The effect of systemically administered recombinant human nerve growth factor in healthy human subjects

• Published in: Annals of neurology Vol. 36; no. 2; p. 244
• Main Authors: Petty, B G, Cornblath, D R, Adornato, B T, Chaudhry, V, Flexner, C, Wachsman, M, Sinicropi, D, Burton, L E, Peroutka, S J
• Format: Journal Article
• Language: English
• Published: United States 01.08.1994
• Subjects: Adolescent; Adult; Antibodies - analysis; Double-Blind Method; Female; Humans; Hyperalgesia - chemically induced; Injections, Subcutaneous; Male; Muscular Diseases - chemically induced; Nerve Growth Factors - administration & dosage; Nerve Growth Factors - pharmacology; Pain - chemically induced; Placebos; Recombinant Proteins - pharmacology

This phase I double-masked, randomized, placebo-controlled study evaluated the safety of single intravenous or subcutaneous doses of recombinant human nerve growth factor (rhNGF) in healthy human volunteers at doses ranging from 0.03 to 1 micrograms/kg. No life-threatening adverse events were seen a...